Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sunitinib malate works in treating patients
with small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC